Table 5.
Impact of immunodeficiency on 60‐d mortality after RSV LRTI in HCT recipients
| Immunodeficiency Grade | Mortality (n = 85) | OR (95% CI) | P‐value |
|---|---|---|---|
| ISI | |||
| Low‐risk | 2/21 (10%) | 1.0 | – |
| Moderate‐risk | 8/43 (19%) | 2.2 (0.4‐11.3) | 0.36 |
| High‐risk | 10/21 (48%) | 10.5 (1.9‐56.6) | 0.01 |
| SID criteria | |||
| MID | 3/39 (8%) | 1.0 | – |
| SID | 5/19 (26%) | 4.3 (0.9‐20.4) | 0.07 |
| vSID | 14/27 (52%) | 11.1 (2.8‐45.1) | <0.001 |
ISI, Immunodeficiency Scoring Index; LRTI, lower respiratory tract infection; MID, moderate immunodeficiency; RSV, respiratory syncytial virus; SID, severe immunodeficiency; vSID, very severe immunodeficiency. Patients with high‐risk ISI or vSID were more likely to die at 60 days after LRTI (in bold).
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.